Content
57
Yahoo Finance
12/10
(Community Post)
Geron CEO Harout Semerjian's statement about "exploring the next steps rapidly" with strong IMpactMF interim data indicates a willingness to pursue an early regulatory filing, but the company's official "base case" remains running the trial to completion in 2028. The full quote, in context from the Q3 2025 earnings call, was: "Our base case is for the trial to run to the final analysis, as is the case for the majority of trials with overall survival as the primary endpoint. Should we see an opportunity to help patients with data from the interim analysis, we will be ready to explore the next steps rapidly". Context and Interpretation "Acting Rapidly" Means Preparing for an Early Filing: The statement is interpreted by analysts as an acknowledgement that exceptionally strong data at the interim analysis could prompt Geron to discuss accelerated approval pathways with regulatory bodies (like the FDA). The "next steps" would …...
Votes:
3
0
57
Yahoo Finance
12/10
(Community Post)
so mf trial patients are living well past the 14 mos survival rate.........say 3 years. . to my recollection any drug that prolongs life even by 3 mos was rewarded.... so now we are talking years.......why isnt trial stopped......you are depriving mf patients.....inhumane.......
Votes:
11
1
57
Yahoo Finance
12/10
(Community Post)
The bashers don't realize what a value this stock is now.Could of bought 10,000 to 50,000 shares below $1.10 several times last 5 months.Watch them chase the tape in 2026 with accelerated revenue growth. Once that happens,big pharma will look at an acquisition at $3.00 to $5.00 in 2026. Cheaper for them to just buygrowth then spend billions on R&D. The Geron board will have to decide whether to go it alone again or just sellout....
Votes:
2
0
57
Yahoo Finance
12/10
(Community Post)
Short Interest 77,603,709 sharesShort Interest Ratio 16.66 Days to CoverShort Interest % Float 14.47 %Almost 17 business days to cover. That is approaching 4 weeks.Goldman and other leveraged buyers will have no problem seeing shortschase tape with market buys in 2026. They are using put options and tax-selling to keeppps down but will reverse course quickly on insider buying and/or new sales guidance from Harout....
57
Yahoo Finance
12/10
(Community Post)
Shares near 5-year low. Hard to believe after all the approvals and the appointment of an ace commercial team that pps still so low. PPS spiked multiple times after year 2000. So many former holders bought and sold. Especially the ones who bailed below $1.10 this year as tutes piled in on cheap shares. 2026 going to be an interesting year on Rytelo growth. Harout will make sure hematologists worldwide know what Rytelo can do vs current MDS drugs. Novartis will open up sales channels abroad and may bid on geron in 2026....
Votes:
3
0
57
Yahoo Finance
12/10
(Community Post)
"There is ongoing momentum and optimism surrounding the sales of Rytelo, the company's recently approved cancer drug. Wall Street analysts have turned more bullish on Geron as it plans to increase its sales push for Rytelo."...
Votes:
4
0
57
Yahoo Finance
12/10
(Community Post)
Danngggg...had to mute UI at least 3x today. Waiting for it to buy shares in early 2026. UI will switch hatsand go long after getting paid a nickel for each post. Goldman employed it since early 2025 since it was doingsuch a good job bashing along with put options, tax selling, and shorting....
Votes:
1
1
57
Yahoo Finance
12/10
(Community Post)
Harout cutting deals worldwide now.Getting good margin even on the large EU ones.Most importantly, getting revenue growth on fast-track like Incy in 2010 and Exas in 2015.That means moving up the timeframe of profitability....
Votes:
2
1
57
Yahoo Finance
12/10
(Community Post)
"At a median follow-up of 45 months (nearly 4 years), an analysis of the Phase 2 IMbark trial data showed a favorable trend toward improved overall survival (OS), progression-free survival (PFS), and time to acute myeloid leukemia (AML) progression for imetelstat-treated patients compared to expected outcomes with best available therapy (BAT) or historical data."...
Votes:
5
0
57
Yahoo Finance
12/10
(Community Post)
huge, "At a median follow-up of 45 months (nearly 4 years), an analysis of the Phase 2 IMbark trial data showed a favorable trend toward improved overall survival (OS), progression-free survival (PFS), and time to acute myeloid leukemia (AML) progression for imetelstat-treated patients compared to expected outcomes with best available therapy (BAT) or historical data."...
Votes:
4
0
57
Yahoo Finance
12/10
(Community Post)
Rytelo is the best therapy to start RS- or 50% of MDS cases. Hands down. How much revenue is that UI? Like $2 billion per year. I would say a 5X multiple minimum on market cap by end of 2026. Conservative $500 million sales in 2026 means $2.5 billion market cap end of 2026....
Votes:
6
2
57
Yahoo Finance
12/10
(Community Post)
ai says this about gern's drug, "At a median follow-up of 45 months (nearly 4 years), an analysis of the Phase 2 IMbark trial data showed a favorable trend toward improved overall survival (OS), progression-free survival (PFS), and time to acute myeloid leukemia (AML) progression for imetelstat-treated patients compared to expected outcomes with best available therapy (BAT) or historical data."...
Votes:
1
1
57
Yahoo Finance
12/10
(Community Post)
huge, "At a median follow-up of 45 months (nearly 4 years), an analysis of the Phase 2 IMbark trial data showed a favorable trend toward improved overall survival (OS), progression-free survival (PFS), and time to acute myeloid leukemia (AML) progression for imetelstat-treated patients compared to expected outcomes with best available therapy (BAT) or historical data."...
Votes:
3
1
57
Yahoo Finance
12/10
(Community Post)
Let's blow through 200-day moving average this week. 1.40 is a done deal.Put some heat on the shorts. Make them cover 20% of their position up to $3.00.Don't sell. I will go on margin later to put more heat on them. Once insider buying or revenue forecasts updated....
Votes:
2
1
57
Yahoo Finance
12/10
(Community Post)
Hi Rocky, before you get too excited, the PII IMbark study concluded a while back and reported results, including OS of 29 or so months in the high dose group. Are you sure your AI platform is not conflating the MDS study with the MF study? Might be worth checking. It's easy to get confused with all the "IM's". The wording sounds very much like Dr. Santini's poster conclusions for the MDS study. This is a very forgivable mistake is that's what happened. We await the PIII MF study comparing Imetelstat with BAT in MF with OS as the primary endpoint. Not estimated to happen until second half of 2026. bp...
Votes:
8
0
57
Yahoo Finance
12/10
(Community Post)
While I am always glad to see Geron close Green, I still must ask the question as to who is trading over 6.6 million shares for a measly gain of only 5 pennies???The news from ASH appeared good - very good, so why not $.30 - $.50 increase over the past few days???We've got a lot of ground to make up if we want to get back into the $5s! If you look at the charts since last March, nothing substantial has happened to increase the PPS. We see only a gradual decline/ drop in the PPS!Of course, IMO....
Votes:
3
1
57
Yahoo Finance
12/10
(Community Post)
the mf trial embark enrolled like 4 y ears ago..it is irrelevant how many patients are enrolled......I believe it has just became fully enrolled......50 percent of patients are still living,obviously or trial would be ended. why not give a detailed update on how many are alive.....why wait,smells fishy,also why not duplicate the mayo 2014 trial in beginning stage of mf......this drug imo has been shelved...
Votes:
2
0
57
Yahoo Finance
12/11
(Community Post)
"Based on 4 Wall Street analysts offering 12 month price targets for Geron in the last 3 months. The average price target is $4.00 with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 225.20% change from the last price of $1.23"...
Votes:
1
0
57
Yahoo Finance
12/11
(Community Post)
"Based on recent analyst reports from the last three months, the average 12-month price target for Geron (GERN) is indeed $4.00, with a high and low forecast of $4.00 as well. This target represents a potential upside of approximately 215% from its last closing price of $1.27 on December 10, 2025. This consensus is derived from the price targets of four Wall Street analysts who issued reports within that 90-day period. The overall analyst consensus rating for Geron is a "Strong Buy," based on these and other recent ratings."...
Votes:
1
0
50
Benzinga
12/11
Why Planet Labs Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Shares of Planet Labs PBC (NYSE: PL) rose sharply in pre-market trading after the company reported better-than-expected third-quarter sales results and issued fourth-quarter sales guidance above estim...
9
EIN News
12/11
Why Planet Labs Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - Agape ATP (NASDAQ:ATPC), Beasley Broadcast Group (NASDAQ:BBGI)
… Planet Labs reported third-quarter revenue of $81.25 million, … market trading. Nextdoor Holdings shares jumped more than 25% … trading after the company reported third-quarter financial results and...
60
Polygon News
12/11
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
Geron Corporation plans to reduce workforce by one-third and streamline operations to improve financial discipline, focusing on RYTELO commercial growth and clinical development while reducing 2026 op...
57
GlobeNewswire
12/11
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
This is a paid press release. Contact the press release distributor directly with any inquiries. Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Cr...
57
Yahoo Finance
12/11
(Community Post)
There's a new sheriff in town. This looks like a very smart and targeted RIF. Many research oriented businesses struggle with the shift to commercial. They tend to chase opportunities (research) as opposed to a focused execution of "what's on the plate". I believe this focus will be rewarded by the market....
Votes:
10
1
57
Yahoo Finance
12/11
(Community Post)
Wow. An actual press release with news in it. One third of the employees gone. I feel sorry for them but I've always felt Geron had way way too many unnecessary employees all paid extremely well.I think blackmarango noted this for years....
Votes:
4
2
57
Yahoo Finance
12/11
(Community Post)
Yeah Fmdck… sure … I can see the tell! Burnrate to high, no sales. Extending cash runway and pushing out Chapter 11. Going alone was the worst decision ever… building up an hyper expensive sales network from scratch to sell only one product competing with Big Pharma… 🤯 probably could have sold to $PFE six years ago for $7/ share before massive dilution but good ol stubborn Chippy was too greedy. 😂...
Votes:
3
2
57
Yahoo Finance
12/11
(Community Post)
"Based on recent analyst reports from the last three months, the average 12-month price target for Geron (GERN) is indeed $4.00, with a high and low forecast of $4.00 as well. This target represents a potential upside of approximately 215% from its last closing price of $1.27 on December 10, 2025. This consensus is derived from the price targets of four Wall Street analysts who issued reports within that 90-day period. The overall analyst consensus rating for Geron is a "Strong Buy," based on these and other recent ratings."...
Votes:
2
3
57
Yahoo Finance
12/11
(Community Post)
"Geron's average total compensation varies widely by role, with general ranges showing Directors earning well into the six figures (e.g., $224K-$327K/yr), Managers around $97K-$143K/yr, and Associates often $64K-$115K/yr, according to Glassdoor"...
Votes:
2
1
62
FinanzNachrichten.de
12/11
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
Restructuring Supports RYTELO- U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE)...
57
Yahoo Finance
12/11
(Community Post)
Hey Never Retirement, based on the just released RESTRUCTURING plan… tell us… what is the Rytelo sales strategy? How can Geron compete with Big Pharma? Will the push out of the ex-US deal have any impact on your retirement plans? I hope you had a second bet on NVDA 😂🫵🏽...
Votes:
2
5
57
Yahoo Finance
12/11
(Community Post)
Short Interest 77,603,709 sharesShort Interest Ratio 16.92 Days to CoverShort Interest % Float 14.47 %Strong buying now to 200-day moving average.Shorts pants on fire. Approaching a month to cover all their shares on weekday trading days with adequate liquidity. Alert! Alert! Alert!...
Votes:
5
2
57
Yahoo Finance
12/11
(Community Post)
Good job Harout. Get rid of the old school from the tenure of Chip.Geron will get to profitability sooner.Most newer employees are sales and customer-service focused. Harout cankeep the best R&D people and have them finish up IMERGE Phase 3....
Votes:
7
0
57
Yahoo Finance
12/11
(Community Post)
Well, Well, WELL!!!!!!!!!!!!!!What do you know!!!I've been posting, FOR YEARS, that Geron had far TOO MANY staff for their corporate operation.So, Harout comes in and what's One Of The First Things That He does?REDUCES STAFF BY 1/3!!! From abut 260, about 86 will be leaving!!!!What did I tell you and then the touters cast "shade" my way!!!Excellent First Step Harout!!!Fact NOT Fiction!!!...
Votes:
10
1
57
Yahoo Finance
12/11
(Community Post)
"A "Golden Cross" in stocks is a bullish technical pattern where a short-term moving average (usually the 50-day) crosses above a long-term moving average (usually the 200-day), signaling strong upward momentum and potential for a sustained uptrend, often seen as a buy signal for traders looking for strong rallies."...
Votes:
7
0
57
Yahoo Finance
12/11
(Community Post)
and this was before todays news, ""Based on recent analyst reports from the last three months, the average 12-month price target for Geron (GERN) is indeed $4.00, with a high and low forecast of $4.00 as well. This target represents a potential upside of approximately 215% from its last closing price of $1.27 on December 10, 2025. This consensus is derived from the price targets of four Wall Street analysts who issued reports within that 90-day period. The overall analyst consensus rating for Geron is a "Strong Buy," based on these and other recent ratings.""...
Votes:
4
0
57
Yahoo Finance
12/11
(Community Post)
Harout likely to give revised revenue and future profitability guidance at qtr1 2026 earnings. Shorts better consider covering in the next month if they can. Goldman has massive buying powerand can borrow cheap money to buy up 5% of float in a week if wants to. The big fish will eat the little ones....
Votes:
5
0
57
Yahoo Finance
12/11
(Community Post)
Finally!! BM you have been opining this for the longest time, now it has come to fruition. The next thing we need to see from Harout is some transparency on sales and sales projections. First off a definition of accounts vs patients prescribed. Does an account represent an entire medical practice or simply a new patient. Seems like a very simple question to answer. So when we hear "150 new accounts" does that mean 150 new users or 150 new practices, who in fact may contain many new end users? Seems like a very, very simple question to which investors are entitled to know the answer . My opinion of course. Best to all longs and Great news today!!...
Votes:
12
0
57
Yahoo Finance
12/11
(Community Post)
Nice to see this finally breaking out on robust volume as predicted...Hopefully it will hold this gain into the close.I guess the strategic structuring plan is being well received.Tale of Two Markets today with the divergence of the Dow and the Naz. Bio index up but GERN trades in it's own universe often and will likely continue to do more of that next year as the company grows revenue and delivers real NEWS...
Votes:
4
0
57
Yahoo Finance
12/11
(Community Post)
"Historically, the golden cross boasts a strong track record in predicting significant price hikes across diverse markets and assets. For instance, the Golden Cross in Bitcoin in April 2019 preceded a price surge of roughly 165% in the following months."...
Votes:
3
0
57
Yahoo Finance
12/11
(Community Post)
"Historically, the golden cross boasts a strong track record in predicting significant price hikes across diverse markets and assets. For instance, the Golden Cross in Bitcoin in April 2019 preceded a price surge of roughly 165% in the following months."...
Votes:
4
0
57
Yahoo Finance
12/11
(Community Post)
Historically, the golden cross boasts a strong track record in predicting significant price hikes across diverse markets and assets. For instance, the Golden Cross in Bitcoin in April 2019 preceded a price surge of roughly 165% in the following months."...
Votes:
2
0
57
Yahoo Finance
12/11
(Community Post)
and this was before todays news, ""Based on recent analyst reports from the last three months, the average 12-month price target for Geron (GERN) is indeed $4.00, with a high and low forecast of $4.00 as well. This target represents a potential upside of approximately 215% from its last closing price of $1.27 on December 10, 2025. This consensus is derived from the price targets of four Wall Street analysts who issued reports within that 90-day period. The overall analyst consensus rating for Geron is a "Strong Buy," based on these and other recent ratings.""...
Votes:
2
0
57
Yahoo Finance
12/11
(Community Post)
Health care deadlock: The Senate failed to advance either the Democratic or Republican proposal to avert rising health care premiums on Thursday, making it all but certain that expanded Affordable Care Act subsidies will expire at the end of the month. Four Republicans joined Democrats in backing a three-year extension of the subsidies, but the plan fell short of the threshold to overcome a filibuster. Republicans likewise failed to advance their plan to replace the subsidies with an expansion of health savings accounts and direct payments to people who buy the most basic plans....
57
Yahoo Finance
12/11
(Community Post)
Immediate Resistance: The stock reached an intra-day high of $1.42 today, which serves as the immediate resistance level. Medium-Term Resistance: The next significant resistance after the intra-day high would be around the $1.60 to $1.80 range, based on a review of recent volume and price history (not explicitly stated in search results, but inferred from charts and 52-week high of over $4). A key technical moving average, the 200-day moving average, is also near the $1.39 mark which is currently being tested....
Votes:
2
0
57
Yahoo Finance
12/11
(Community Post)
as much as I want the savings of restructuring, I feel badly for the approximately 80 employees looking at being fired. thanking them for their contributions does not put food on the table. I wish there was another way!!!!...
Votes:
3
2
57
Yahoo Finance
12/11
(Community Post)
and this was before todays news! ""Based on recent analyst reports from the last three months, the average 12-month price target for Geron (GERN) is indeed $4.00, with a high and low forecast of $4.00 as well. This target represents a potential upside of approximately 215% from its last closing price of $1.27 on December 10, 2025. This consensus is derived from the price targets of four Wall Street analysts who issued reports within that 90-day period. The overall analyst consensus rating for Geron is a "Strong Buy," based on these and other recent ratings.""...
Votes:
2
0
57
Yahoo Finance
12/11
(Community Post)
and this was before todays news! ""Based on recent analyst reports from the last three months, the average 12-month price target for Geron (GERN) is indeed $4.00, with a high and low forecast of $4.00 as well. This target represents a potential upside of approximately 215% from its last closing price of $1.27 on December 10, 2025. This consensus is derived from the price targets of four Wall Street analysts who issued reports within that 90-day period. The overall analyst consensus rating for Geron is a "Strong Buy," based on these and other recent ratings.""...
Votes:
3
2
57
Yahoo Finance
12/11
(Community Post)
Alpha Spread AI report said Geron Intrinsic value is 5.66. So geron 77% undervalued. 500 million sales in 2026 not a pipe dream. 33% less costs that year from less employees. 5X sales = 5 x $500 million = $2.5 billion market cap.That should give a $4.00 price end of 2026....
Votes:
3
1
57
Yahoo Finance
12/11
(Community Post)
Yesterday, ""Based on recent analyst reports from the last three months, the average 12-month price target for Geron (GERN) is indeed $4.00, with a high and low forecast of $4.00 as well. This target represents a potential upside of approximately 215% from its last closing price of $1.27 on December 10, 2025. This consensus is derived from the price targets of four Wall Street analysts who issued reports within that 90-day period. The overall analyst consensus rating for Geron is a "Strong Buy," based on these and other recent ratings.""...
Votes:
2
1
57
Yahoo Finance
12/11
(Community Post)
what happens to the options granted to the employees that get let go. I assume they evaporate - worthless, if under water... at least those that have not vested yet. what about RSUs that have not vested yet? again, I assume they evaporate....
Votes:
1
0
57
Yahoo Finance
12/11
(Community Post)
Yesterday, ""Based on recent analyst reports from the last three months, the average 12-month price target for Geron (GERN) is indeed $4.00, with a high and low forecast of $4.00 as well. This target represents a potential upside of approximately 215% from its last closing price of $1.27 on December 10, 2025. This consensus is derived from the price targets of four Wall Street analysts who issued reports within that 90-day period. The overall analyst consensus rating for Geron is a "Strong Buy," based on these and other recent ratings.""...
Votes:
1
0
57
Yahoo Finance
12/11
(Community Post)
ai Yesterday, ""Based on recent analyst reports from the last three months, the average 12-month price target for Geron (GERN) is indeed $4.00, with a high and low forecast of $4.00 as well. This target represents a potential upside of approximately 215% from its last closing price of $1.27 on December 10, 2025. This consensus is derived from the price targets of four Wall Street analysts who issued reports within that 90-day period. The overall analyst consensus rating for Geron is a "Strong Buy," based on these and other recent ratings.""...
Votes:
3
0
57
Yahoo Finance
12/11
(Community Post)
gern stock just blew through the golden cross today, and historically, the golden cross boasts a strong track record in predicting significant price hikes across diverse markets and assets. For instance, the Golden Cross in Bitcoin in April 2019 preceded a price surge of roughly 165% in the following months."...
Votes:
3
0
57
Yahoo Finance
12/11
(Community Post)
Is the worm turning?Miami Mayor, a DemocratIndiana Lawmakers Reject Trump’s New Political MapRepublicans hold an overwhelming majority in the Indiana Senate, but more than a dozen of them defied the president’s wishes, voting against a map aimed at adding Republicans in Congress....
57
Yahoo Finance
12/11
(Community Post)
the gern stock just blew through the golden cross today, and historically, the golden cross boasts a strong track record in predicting significant price hikes across diverse markets and assets. For instance, the Golden Cross in Bitcoin in April 2019 preceded a price surge of roughly 165% in the following months."...
Votes:
1
0
57
Yahoo Finance
12/11
(Community Post)
The Rule of Law or a King?Trump announced the "pardon" of Peters in a Dec. 11 post on X. However, Peters ‒ who remains the only Trump ally in prison for crimes related to attempts to overturn the 2020 election ‒ was convicted on state charges. Trump's pardon power as president only extends to federal charges, meaning Peters will remain in prison and her conviction stands....
57
Yahoo Finance
12/11
(Community Post)
the gern stock just blew through the golden cross today, and historically, the golden cross boasts a strong track record in predicting significant price hikes across diverse markets and assets. For instance, the Golden Cross in Bitcoin in April 2019 preceded a price surge of roughly 165% in the following months."...
Votes:
2
0
57
Yahoo Finance
12/11
(Community Post)
remember…companies dont get sold (and precisely why the decades old talk of “he was brought in to sell the company was so…amateurish)..companies get BOUGHT…and today begins the waxing and polishing… lessons available upon request (except for Morono…)...
Votes:
2
1
57
Insider Monkey
12/11
Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting
Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting Noor Ul Ain Rehman Thu, December 11, 2025 at 11:40 PM EST 2 min read GERN Geron Corporation (N...
57
Yahoo Finance
12/11
(Community Post)
the gern stock just blew through the golden cross today, and historically, the golden cross boasts a strong track record in predicting significant price hikes across diverse markets and assets. For instance, the Golden Cross in Bitcoin in April 2019 preceded a price surge of roughly 165% in the following months."...
Votes:
1
0
57
Yahoo Finance
12/11
(Community Post)
dementia is taking trump in his first year of his term and took joe biden in his third year both men we now can agree are too old to be credible and then add to the fact trump is crude ,insulting ,and genuinely insulting to the female reporters, let's agree no more electing old people to be potus. imo....
57
Yahoo Finance
12/11
(Community Post)
the gern stock just blew through the golden cross, and historically, the golden cross boasts a strong track record in predicting significant price hikes across diverse markets and assets. For instance, the Golden Cross in Bitcoin in April 2019 preceded a price surge of roughly 165% in the following months."...
Votes:
1
0
57
Yahoo Finance
12/12
(Community Post)
Donny Demento is slowing up. His health is bad. His brain is mush. His ego has swollen to the size of a thousand suns. He’s transformed 1600 Pennsylvania Avenue from a dignified seat of American governance to a gold-gilded cuckoo’s nest of his own design. And, for some reason, most of the American establishment is still bending over backward to avoid saying the obvious: The Burger King is cooked....
57
Yahoo Finance
12/12
(Community Post)
Donny Demento is slowing up. His health is bad. His brain is mush. His ego has swollen to the size of a thousand suns. He’s transformed 1600 Pennsylvania Avenue from a dignified seat of American governance to a gold-gilded cuckoo’s nest of his own design. And, for some reason, most of the American establishment is still bending over backward to avoid saying the obvious: The Burger King is cooked....
57
Yahoo Finance
12/12
(Community Post)
Donny Demento is slowing up. His health is bad. His brain is mush. His ego has swollen to the size of a thousand suns. He’s transformed 1600 Pennsylvania Avenue from a dignified seat of American governance to a gold-gilded cuckoo’s nest of his own design. And, for some reason, most of the American establishment is still bending over backward to avoid saying the obvious: The Burger King is cooked....
57
Yahoo Finance
12/12
(Community Post)
And let’s get to the really good stuff before, you know, it’s a crime to talk about it: the bizarre bragging about the fact that he’s had to get multiple cognitive exams tests. He makes a point of stating that no other president has gone through the battery of tests to which he has been subjected. The reason, unstated: most other presidents haven’t demonstrated the level of cognitive impairment our current one displays on a minute-to-minute basis....
57
Yahoo Finance
12/12
(Community Post)
Let me be frank: The President of the United States is out of his mind, and nobody’s doing a thing about it. What do I mean? Any number of red flags, really, but in particular right now it’s the latest five hundred words of blithering lunacy he shared on his bitcoin mining operation social media site Tuesday night....
57
Yahoo Finance
12/12
(Community Post)
the gern stock just blew through the golden cross, and historically, the golden cross boasts a strong track record in predicting significant price hikes across diverse markets and assets. For instance, the Golden Cross in Bitcoin in April 2019 preceded a price surge of roughly 165% in the following months."...
Votes:
1
1
57
Yahoo Finance
12/12
(Community Post)
ai Yesterday, ""Based on recent analyst reports from the last three months, the average 12-month price target for Geron (GERN) is indeed $4.00, with a high and low forecast of $4.00 as well. This target represents a potential upside of approximately 215% from its last closing price of $1.27 on December 10, 2025. This consensus is derived from the price targets of four Wall Street analysts who issued reports within that 90-day period. The overall analyst consensus rating for Geron is a "Strong Buy," based on these and other recent ratings.""...
Votes:
2
2
57
Yahoo Finance
12/12
(Community Post)
the gern stock just blew through the golden cross, and historically, the golden cross boasts a strong track record in predicting significant price hikes across diverse markets and assets. For instance, the Golden Cross in Bitcoin in April 2019 preceded a price surge of roughly 165% in the following months."...
Votes:
2
2
57
Yahoo Finance
12/12
(Community Post)
ai Yesterday, ""Based on recent analyst reports from the last three months, the average 12-month price target for Geron (GERN) is indeed $4.00, with a high and low forecast of $4.00 as well. This target represents a potential upside of approximately 215% from its last closing price of $1.27 on December 10, 2025. This consensus is derived from the price targets of four Wall Street analysts who issued reports within that 90-day period. The overall analyst consensus rating for Geron is a "Strong Buy," based on these and other recent ratings.""...
Votes:
1
1
57
Yahoo Finance
12/12
(Community Post)
question for touts , why are we stuck in the mud at 1.36 when we hit 1.41 yesterday ? going on 2 years approval from fda ,what we got positive yesterday was we will become profitable by firing the scarlett fat to get us to profitability, then maybe we get a big pharma offer of 5 buck chuck. imo....
57
Yahoo Finance
12/12
(Community Post)
"It took Geron more than three decades to score an approval for Rytelo (imetelstat), which finally arrived by way of an FDA nod for the telomerase inhibitor in MDS last June. Evaluate has previously estimated that sales for Rytelo could reach $737 million in 2028.""Could reach $738 million"??? 😂...
Votes:
2
1
57
Yahoo Finance
12/12
(Community Post)
Everything is going better than i hoped on Harout's re-organization. Awesome to lower the head count. That will save millions in 2026. Let's assume $300K per person for wages, health care, et. That's $24 million saved. AI can do most their work.I strongly suspect that Novartis will help on EU sales channels and probably get a new board member at Geron to watch over things. When Goldman gets enough shares, it will try getting a board member too. If you read more about imetelstat, it is being used in more R&D on other cancers. Maia is using it on small tumor cancers. Good for maia. Get the word out on imetelstat....
57
Yahoo Finance
12/12
(Community Post)
Short Interest 77,603,709 sharesShort Interest Ratio 11.97 Days to CoverShort Interest % Float 14.47 %I see tax-loss selling still happening here.Inevitable due to gains in AI stocks like Nvidia and wanting to lower tax bill.The hedge funds can keep the pps low for rest of 2025 if they want. 2026 different story. Healthcare funds like XBI looking for winners to sell more.Geron ready to be added to their lineup. XBI could easily triple % of geron shares and jettison losers to keep its fund looking good in 2026. XBI took a huge hit after Covid ended. Don't imagine they want to repeat that again....
Votes:
2
0
57
Yahoo Finance
12/12
(Community Post)
""Based on recent analyst reports from the last three months, the average 12-month price target for Geron (GERN) is indeed $4.00, with a high and low forecast of $4.00 as well. This target represents a potential upside of approximately 215% from its last closing price of $1.27 on December 10, 2025. This consensus is derived from the price targets of four Wall Street analysts who issued reports within that 90-day period. The overall analyst consensus rating for Geron is a "Strong Buy," based on these and other recent ratings.""...
Votes:
5
0
57
Yahoo Finance
12/12
(Community Post)
Harout not making friends at geron but he was not brought onboard for that.Harout has a big stock reward to get the pps way up on 2026. His latest 33% layoff isthe right way. Trim the fat like GE used to. He has enough loyal staff on hand to be laser-focused on execution.77 million short shares are playin with fire now. They think just because so many shares to be safe.Not correct. The tutes own most of this company now and will NOT sell any below $4. They have almostunlimited buying power by borrowing cheap money against assets and buying up 5% of this thing in aweek's time.Whether Harout is preparing Geron for a sale or huge revenue growth is not set yet by him yet.One thing for sure. This is not being sold for anything below $4.00. That is 1.77 below intrinsic value....
Votes:
2
1
57
Yahoo Finance
12/12
(Community Post)
stock picker ,I guess its suits you to make it up as you go ,but I will say this again ,the institutions are and have been both long and short as insurance and used by scarlett to buoy the share price while he massively di-looted this company ,so stop spreading the inference of a potential squeeze ,ain't happening....
57
Yahoo Finance
12/12
(Community Post)
Harout doing more deals as we chat here.The guy is a master in sales, pricing, and cost-cutting.2026 going to be the year or huge revenue spike like Incy in 2010 and Exas in 2015. Exas just got bought for $21 billion. Not even profitable but huge growth in cancer testing....
Votes:
2
1
57
Yahoo Finance
12/12
(Community Post)
Zero-sum game now and short holders on wrong side of trade.77 million mistakes ready to chase the tape in early 2026. Will take weeks,if not a month to cover that many shares. Insider buying with share buyback announcementin early 2026 would be lethal to shorts. Harout knows that buying a cheap shares back is a good investment on earnings acceleration. Goldman would lend them cheap money in an instant....
Votes:
2
0
57
Yahoo Finance
12/12
(Community Post)
I can’t be the only one who enjoys watching night vision video of drug boats being eviscerated. Adds to the holiday spirit when we spent the last season in a hospital watching a relative cling to life after an overdose. So yes Kenny I enjoy watching Don Pete and the military send these demons back to where they came from...
(Community Post)